Treatment of cancer in a patient comprises administering to the patient an effective amount of an antibody and an effective amount of NK cells, wherein the antibody binds an antigen on the surface of the NK cells and the antibody binds to an Fc receptor on a cell of the cancer. Anticancer activity is via resultant killing action of the NK cell on the cancer cell now binding the antibody via R-ADCC.